Can the Oil Market Absorb OPEC+ Output Hikes?
Short it was, but the size of the increase for August was bigger than expected— 548,000 bpd. The eight OPEC+ members that are unwinding the cuts are expected to make another supersized increase in September, with which the 2.2 million bpd cuts will all be back on the market, at least the headline figures suggest so.
However, no one is really sure by how much OPEC+ is actually raising oil production these days because some producers are pumping less than quotas to compensate for previous overproduction. Analysts concur that the supersized hikes are not that supersized.OPEC+ continues to rely on strong summer oil demand to absorb the additional barrels. The physical market appears to be tight in the near term, although the coming glut in the autumn and beyond is likely to push oil prices further down.
Oil didn't collapse following this weekend's OPEC+ decision—a sign that there isn't immediate fear of oversupply and that the market hasn't shaken off entirely geopolitics-driven volatility.
Immediately after the OPEC+ meeting, Saudi Arabia raised the official selling price (OSP) for its crude destined for Asia and Europe in August, betting on robust summer demand to soak up the additional supply.Current oil prices in the $60s per barrel are likely to encourage buying in Asia, as China continues to stockpile crude with high purchases at lower oil prices.
May and June arrivals are set to be strong as cargoes contracted a month or two earlier were at prices near four-year lows.
But much of the July, and especially August, supply was likely contracted in June, when oil spiked to four-month highs amid the Israel-Iran war. This suggests that Asian buyers, including top Asian crude importers China and India, likely bought lower volumes when prices were high.
Since the ceasefire announced by U.S. President Donald Trump at the end of June, prices have largely returned to pre-conflict levels, allowing again price-sensitive opportunistic buyers to seek more supply.
The current oil price, with Brent Crude in the high $60s per barrel, is the 'right place' for crude prices, AS Sahney, chairman of state-owned Indian Oil Corporation, the biggest refiner in India, said earlier this week.
'There is still some room for it to go downwards. What I see is very much near to $65, plus or minus one or two dollars, is the right place where we will be comfortable,' Sahney told the NDTV Profit outlet on Monday.
If the strong Asian imports in May were largely due to low oil prices, then overall Asian demand later this summer may disappoint, as volumes contracted in June will be much lower due to the war premium in prices for most of last month.
Hence, demand may not be as strong as it appears to be, Reuters columnist Clyde Russell argues.The market is still tight in the near term, with the tightness reflected in the strength in the prompt Brent timespread, ING commodities strategists Warren Patterson and Ewa Manthey wrote in a note on Tuesday.
'The expected supply surplus won't materialise until later this year, when we expect more sustained downward price pressure,' they added.
The middle distillate market is also tightening, more so than the crude market. Gasoil refining margins are rising, while speculators hold the largest net long position – the difference between bullish and bearish bets – in gasoil for a year, according to ING.
In the United States, middle distillate inventories sit at their lowest level in more than two decades for this time of the year, the bank's strategists noted.
Saudi Aramco's crude price hikes to all regions for August-loading cargoes also signal that physical markets remain tight, 'suggesting the additional barrels can be absorbed—for now,' Ole Hansen, Head of Commodity Strategy at Saxo Bank, wrote in a Monday note.
'In the short term, downside risks to crude appear contained,' Hansen said.
'Compensation cuts from previous overproduction are helping offset new supply, while geopolitical uncertainty in the Middle East continues to discourage aggressive short positioning by speculators.'
Recent consensus-beating economic data from the United States support a steady demand outlook, but continued trade tensions and tariff announcements somewhat dampen the bullish sentiment. In addition, 'seasonal demand softening into autumn could emerge as headwinds in the months ahead,' Hansen noted.
Despite signs of current physical market tightness, analysts do not expect prices to top $70 per barrel for a sustained period of time, barring another major escalation in the Middle East.
Growing supply from the OPEC+ group, although not as high as the monthly headline figures suggest, is set to create an oversupply on the market going into autumn, even if summer demand holds strong. On the demand side, peak summer travel season may justify higher supply, but lingering trade and economic uncertainties may cap upside to prices.
By Tsvetana Paraskova for Oilprice.com
More Top Reads From Oilprice.com:Read this article on OilPrice.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Car import quotas, export credits on table for EU-US trade talks, sources say
By Christoph Steitz, Julia Payne and David Lawder FRANKFURT/BRUSSELS/WASHINGTON (Reuters) -Brussels is discussing with U.S. counterparts a range of measures aimed at protecting the European Union's auto industry from steep U.S. import duties, including tariff cuts, import quotas and credits against the value of EU automakers' U.S. exports, industry sources and trade officials say. The talks are part of efforts by the European Commission, the bloc's executive branch, to reach a trade agreement outline with the United States in the coming days, ahead of the August 1 deadline set by U.S. President Donald Trump for broad tariff increases. Trump said on Tuesday he would "probably" tell the EU within two days what rate it could expect for its exports to the U.S., adding that the 27-nation bloc had become much more cooperative. EU negotiators have sought relief from tariffs in key sectors such as autos and aerospace. One EU diplomat previously said cars were a "red line" for the bloc, making a U.S. concession on cars a caveat of any deal. Since April, EU carmakers have incurred a 25% U.S. import tariff on top of the 2.5% already in place. The levy is separate from Trump's prior threatened 20% "reciprocal" tariff announced in April but dialed back to 10%. Discussions are ongoing and it is unclear if the U.S. administration will agree to all terms from its biggest bilateral trading partner, the sources said. The White House, the U.S. Trade Representative's Office and the Commerce Department did not immediately respond to requests for comment on the U.S.-EU negotiations. The European Commission also had no immediate comment for this story. EU trade chief Maros Sefcovic said on Wednesday the Commission has made good progress on a framework trade agreement with the United States and a deal may be possible in the coming days. The sources - two European industry sources, three European officials and three U.S. industry sources familiar with the talks - declined to be identified because the talks are confidential. EXPORT CREDITS A U.S. source and one European official said things are moving "fast" in the negotiations. On the table is a proposal that would provide some relief from import tariffs for carmakers that produce vehicles in the United States and export them to other countries, three of the sources said. Under that plan, carmakers that export vehicles from the U.S. would get credits for that export value, which could then be applied against the value of any imports from the EU into the U.S., the U.S. source said. That would allow companies to import that value of vehicle duty-free or at a reduced rate, while anything above it would be subject to the maximum tariff. Such a mechanism would benefit carmakers BMW and Mercedes-Benz, which both have major production hubs in the United States for sport-utility vehicles, with a significant share of their output exported. Two sources said the U.S. had offered some relief if a company agrees to make additional investment, a mechanism that would help Volkswagen, which barely exports out of U.S. plants but is weighing a local factory for its Audi brand. The terms are a delicate balancing act for Brussels as it tries to find concessions that are acceptable to carmakers such as BMW, Porsche, Volkswagen and Mercedes-Benz, as well as to the Trump administration, which wants to boost U.S. manufacturing and create jobs. TARIFF RATES, QUOTAS DISCUSSED Europe shipped nearly 758,000 cars worth 38.9 billion euros ($45.57 billion) to the U.S. in 2024, more than four times as many as in the other direction, according to data from European auto association ACEA. Two of the sources said the framework may be similar to the one agreed with Britain in May. In that deal, the U.S. cut tariffs on British-made cars to 10% and British carmakers received a import quota of 100,000 cars a year at the lower tariff rate, almost the total Britain exported last year. While the EU had proposed a similar tariff-rate quota with a certain number of vehicles imported, two U.S. industry sources said the Trump administration was leaning against this. Three sources said both sides have discussed cutting their respective auto import tariffs from current levels - 27.5% for imports into the U.S., and 10% for imports into the EU. Non-tariff elements such as standardising regulation, for example in the area of auto safety tests, are also being offered by the EU, one of the people said. ($1 = 0.8536 euros) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance
Jason Campagna, MD, PhD, joins Inventiva as President of R&D and Chief Medical Officer, succeeding Pierre Broqua, PhD, and Michael Cooreman, MD Martine Zimmermann, PharmD, joins as Executive Vice President of Regulatory Affairs and Quality Assurance These key leadership appointments underscore Inventiva's commitment to long-term growth and operational excellence, with topline results from NATiV3 on track for the second half of 2026 Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ('Inventiva' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ('MASH'), today announced a leadership transition with the appointment of Jason Campagna, MD, PhD, as President of Research and Development ('R&D') and Chief Medical Officer ('CMO') and Martine Zimmermann, PharmD, as Executive Vice President ('EVP') of Regulatory Affairs and Quality Assurance. Dr. Campagna is joining Inventiva's executive leadership team and brings extensive expertise in the MASH field. He succeeds Pierre Broqua, PhD, co-founder and Chief Scientific Officer, who is transitioning to a consulting role as Scientific Advisor, and Michael Cooreman, MD, departing as CMO of the Company. Dr. Campagna most recently was the CMO at Q32 Bio and prior to that was the MASH Global Program Lead and CMO at Intercept Pharmaceuticals. Dr. Zimmermann is also joining the Company's executive leadership team. She was most recently Senior Vice President, Head of Regulatory Affairs at Ipsen where she successfully led a team that secured regulatory approvals of two liver disease drugs, including Iqirvo®, a dual PPARα/δ agonist, for the treatment of primary biliary cholangitis. Prior to Ipsen, Dr. Zimmermann was Senior Vice President and Head of Global Regulatory Affairs & Quality at Alexion Pharma (also known as AstraZeneca Rare Disease). Frederic Cren, CEO of Inventiva stated: 'Jason and Martine both bring exceptional leadership and experience during this pivotal time for the Company as we plan for the readout of our NATiV3 Phase 3 study next year and lanifibranor's potential regulatory approval and commercialization. Having played an integral part in the creation and building of Inventiva, Pierre will continue to actively support the team in a scientific consulting role. I would also like to express my gratitude to Michael for his scientific leadership and contributions in advancing lanifibranor to this stage and we wish him every success in his future endeavors.' Jason Campagna, MD, PhD, President, R&D and CMO of Inventiva commented: 'Inventiva has built a robust scientific and clinical foundation, and I'm thrilled to join the team at this pivotal moment as we advance lanifibranor toward anticipated regulatory submissions. Having led the design and execution of one of the field's most advanced clinical programs at Intercept—including the first-ever NDA submission in this indication—I've seen firsthand both the scientific complexity and the urgency of bringing effective therapies to patients with MASH. I believe the promising results of the Phase 2b NATIVE trial reflect the thoughtful design of lanifibranor development program—and that's deeply exciting to me. With lanifibranor well on its way in the Phase 3 NATiV3 registrational trial, I look forward to working closely with the exceptional team at Inventiva to deliver on the promise of bringing a novel treatment to patients with MASH.' Martine Zimmermann, PharmD, Executive Vice President of Regulatory Affairs and Quality Assurance of Inventiva said: "I'm excited to take on this leadership role at a time when Inventiva is entering a critical regulatory phase for lanifibranor, a first-in-class pan-PPAR agonist for the treatment of MASH. In my career, I've been closely involved in leading global regulatory strategy and approval of compounds for the treatment of chronic liver diseases, including a PPAR, in a number of geographies, including the US, Europe and Japan. I am now eager to apply that experience to support lanifibranor toward a potential approval." About Inventiva Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). Contacts InventivaPascaline ClercEVP, Strategy and Corporate Affairsmedia@ 202 499 8937 ICR HealthcareMedia relations Alexis Feinberg inventivapr@ +1 203 939 2225 ICR HealthcarePatricia L. BankInvestor relations +1 415 513 1284 Important Notice This press release contains certain 'forward-looking statements' within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, Inventiva's clinical trials, including Inventiva's ongoing NATiV3 Phase 3 clinical trial of lanifibranor in MASH, including related timing and regulatory matters with respect thereto, clinical trial data releases and publications, the information, insights and impacts that may be gathered from clinical trials, the potential therapeutic benefits of Inventiva's product candidates, potential regulatory submissions, approvals and commercialization, the effective start date of Dr. Campagna and Mrs. Zimmerman, the clinical development of and regulatory plans and pathway for lanifibranor, and future activities, expectations, plans, growth and prospects of Inventiva. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, 'believes', 'anticipates', 'expects', 'intends', 'plans', 'seeks', 'estimates', 'may', 'will', 'would', 'could', 'might', 'should', 'designed', 'hopefully', 'target', 'potential', 'possible', 'aim', and 'continue' and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance, or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Future results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates due to a number of factors, including that interim data or data from any interim analysis of ongoing clinical trials may not be predictive of future trial results, the recommendation of the DMC may not be indicative of a potential marketing approval, Inventiva cannot provide assurance on the impacts of the Suspected Unexpected Serious Adverse Reaction on the results or timing of the NATiV3 trial or regulatory matters with respect thereto, that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, in the absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research or development programs or be unable to expand its operations or otherwise capitalize on its business opportunities and may be unable to continue as a going concern, Inventiva's ability to obtain financing, to enter into potential transactions, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of lanifibranor, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's and its partners' clinical trials may not support Inventiva's and its partners' product candidate claims, Inventiva's expectations with respect to its clinical trials may prove to be wrong and regulatory authorities may require additional holds and/or amendments to Inventiva's clinical trials, Inventiva's expectations with respect to the clinical development plan for lanifibranor for the treatment of MASH may not be realized and may not support the approval of a New Drug Application, Inventiva's ability to identify additional products or product candidates with significant commercial potential, Inventiva's expectations with respect to its pipeline prioritization plan and related workforce reduction, including whether the plan will be implemented and the timing, potential benefits, expenses and consequences relating thereto, Inventiva's ability to execute on its commercialization, marketing and manufacturing capabilities and strategy, Inventiva's ability to successfully cooperate with existing partners or enter into new partnerships, and to fulfill its obligations under any agreements entered into in connection with such partnerships, the benefits of its existing and future partnerships on the clinical development, regulatory approvals and, if approved, commercialization of its product candidates, and the achievement of milestones thereunder and the timing thereof, Inventiva and its partners may encounter substantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, the ability of Inventiva and its partners to recruit and retain patients in clinical studies, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's and its partners' control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva's and its partners' business, and pre-clinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by changes in law and regulations, unfavorable conditions in its industry, geopolitical events, such as the conflict between Russia and Ukraine and related sanctions, the conflict in the Middle East and the related risk of a larger conflict, health epidemics, and macroeconomic conditions, including developments in international trade policies, global inflation, financial and credit market fluctuations, tariffs and other trade barriers, political turmoil and natural catastrophes, uncertain financial markets and disruptions in banking systems. The review of potential financial and strategic options may not result in any particular action or transaction being pursued, entered into or consummated, and there is no assurance as to the timing, sequence or outcome of any action or transaction or series of actions or transactions. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts, and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Please refer to the Universal Registration Document for the year ended December 31, 2024, filed with the Autorité des Marchés Financiers on April 15, 2025, and the Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (the 'SEC') on April 15, 2025 for other risks and uncertainties affecting Inventiva, including those described under the caption 'Risk Factors' and in future filings with the SEC. Other risks and uncertainties of which Inventiva is not currently aware may also affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements. Attachment Inventiva - PR - Leadership Team Changes- EN - 07 09 2025Sign in to access your portfolio
Yahoo
17 minutes ago
- Yahoo
Range Rover Has a Funky New Secondary Logo and a Pattern to Match
Jaguar , now JLR, has a funky new logo for Range Rover to help distinguish the brand as part of JLR's recent House of Brands strategy. The new logo features stacked and mirrored Rs, with the brand also showing a new checker pattern built up of Range Rover Rs in interlocking circles. Don't be alarmed, as the brand told it won't replace the script logo found on the front and rear of every model. JLR is sporting a new logo for its Range Rover brand, now that it can't exist as a sub-brand under Land Rover. Autocar broke the news, spotting the logo in a recent JLR investor presentation. The new logo features a set of stacked and mirrored Rs in the brand's typical script. Jaguar previously revealed its new minimalist set of logos, including a typeface that mixes uppercase and lowercase letters, but we're still waiting for dedicated rebrands for the Discovery and Defender SUVs. The brand also revealed what it is calling the "Range Rover Pattern," which is effectively a new checker pattern of interlocking and rotated Range Rover Rs. The automaker hasn't announced how it plans to use the new pattern, but we wouldn't be surprised to find it in future Range Rover front ends, or as part of the upholstery of future models. The new logo and motif aren't intended to replace the "Range Rover" script badging on the front and rear of every model. "The Range Rover Motif has been developed as a smaller symbol for where our familiar Range Rover device mark does not fit, such as on a label or as part of a repeating pattern, and within event spaces where an emblem is more appropriate," a JLR spokesperson confirmed to Car and Driver. You Might Also Like Car and Driver's 10 Best Cars through the Decades How to Buy or Lease a New Car Lightning Lap Legends: Chevrolet Camaro vs. Ford Mustang!
